Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 11: Antibody-drug conjugates
Submit an article Journal homepage
772
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Antibody–drug conjugates targeting HER2-mutant or HER2-(non) amplified solid tumors: is HER2 an agnostic target?

Lorenzo Guidia Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyView further author information
,
Carmine Valenzaa Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyView further author information
,
Dario Trapania Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyView further author information
&
Giuseppe Curiglianoa Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy;b Department of Oncology and Hemato-Oncology, University of Milan, Milan, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1781-2518View further author information
ORCID Icon
Pages 1039-1042 | Received 19 Sep 2023, Accepted 27 Oct 2023, Published online: 01 Nov 2023

Figures & data

Figure 1. The spectrum of activity of HER2-targeting agents across solid tumors, according to HER2 status. Created with Biorender.com.

ADC, antibody–drug conjugate; CRC, colorectal cancer; HER2, Human Epidermal Growth Factor Receptor 2; ISH, in situ hybridization; mAb, monoclonal antibody; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.
Figure 1. The spectrum of activity of HER2-targeting agents across solid tumors, according to HER2 status. Created with Biorender.com.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.